[Chromogranin A and neuroendocrine tumors]
- PMID: 23271036
- DOI: 10.1016/j.endonu.2012.10.003
[Chromogranin A and neuroendocrine tumors]
Abstract
Chromogranin A (CgA) is the most abundant granin in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). As a tumor marker is moderately sensitive and nonspecific. Despite the limitations of testing methods, which require careful interpretation, especially in the case of gastrinomas, patients treated with somatostatin analogues, and poorly differentiated tumors, it is the best tumor marker in GEP-NETs and may be of value in other tumors with neuroendocrine differentiation. CgA may be used as a marker in blood or tissue samples through immunohistochemical techniques. CgA levels correlate with tumor burden and extension and may be used for diagnosis and monitoring of GEP-NETs, especially midgut carcinoids and endocrine pancreatic tumors. It is also useful as a prognostic marker for detection of recurrence and monitoring of response to different treatments.
Keywords: Chromogranin A; Cromogranina A; Gastrinoma; Gastroenteropancreatic neuroendocrine tumors; Tumores neuroendocrinos gastroenteropancreáticos.
Copyright © 2012 SEEN. Published by Elsevier Espana. All rights reserved.
Similar articles
-
[The diagnostic value of plasma chromogranin A in neuroendocrine tumors].Zhonghua Nei Ke Za Zhi. 2011 Feb;50(2):124-7. Zhonghua Nei Ke Za Zhi. 2011. PMID: 21418832 Chinese.
-
The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.Endocrinol Metab Clin North Am. 2011 Mar;40(1):111-34, viii. doi: 10.1016/j.ecl.2010.12.001. Endocrinol Metab Clin North Am. 2011. PMID: 21349414 Review.
-
Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.J Clin Endocrinol Metab. 1997 Aug;82(8):2622-8. doi: 10.1210/jcem.82.8.4145. J Clin Endocrinol Metab. 1997. PMID: 9253344
-
Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.Expert Rev Gastroenterol Hepatol. 2012 Jun;6(3):313-34. doi: 10.1586/egh.12.15. Expert Rev Gastroenterol Hepatol. 2012. PMID: 22646254 Review.
-
Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.Acta Gastroenterol Latinoam. 2009 Sep;39(3):184-9. Acta Gastroenterol Latinoam. 2009. PMID: 19845257
Cited by
-
A novel bioengineered fragment peptide of Vasostatin-1 exerts smooth muscle pharmacological activities and anti-angiogenic effects via blocking VEGFR signalling pathway.Comput Struct Biotechnol J. 2021 May 3;19:2664-2675. doi: 10.1016/j.csbj.2021.05.003. eCollection 2021. Comput Struct Biotechnol J. 2021. PMID: 34093983 Free PMC article.
-
Incidence and prevalence of gastric neuroendocrine tumors in patients with chronic atrophic autoimmune gastritis.World J Gastrointest Oncol. 2023 Aug 15;15(8):1451-1460. doi: 10.4251/wjgo.v15.i8.1451. World J Gastrointest Oncol. 2023. PMID: 37663936 Free PMC article.
-
Recurrent transient visual loss in secretory carcinoid tumor.Am J Ophthalmol Case Rep. 2025 Feb 23;38:102289. doi: 10.1016/j.ajoc.2025.102289. eCollection 2025 Jun. Am J Ophthalmol Case Rep. 2025. PMID: 40104203 Free PMC article.
-
Biological function and clinical relevance of chromogranin A and derived peptides.Endocr Connect. 2014 Apr 29;3(2):R45-54. doi: 10.1530/EC-14-0027. Print 2014. Endocr Connect. 2014. PMID: 24671122 Free PMC article.
-
Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.BMC Endocr Disord. 2017 Jul 13;17(1):39. doi: 10.1186/s12902-017-0190-6. BMC Endocr Disord. 2017. PMID: 28705205 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous